Molecular Partners AG
MOLN
Cena:
$ 4.18
+0.38 (10.00%)
Valuace
70
Růst
30
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
MOLECULAR PARTNERS ANNOUNCES PRESENTATION OF FIRST IMAGING AND DOSIMETRY DATA OF DLL3-TARGETING RADIOTHERAPY MP0712 IN PATIENTS AT TWC 2026
02-02-2026
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., FEB. 02, 2026 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS TO PRESENT AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
18-12-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., DEC. 18, 2025 (GLOBE NEWSWIRE) -- MOLECULAR PARTNE...
Více zde
MOLECULAR PARTNERS PRESENTS UPDATED DATA FROM ONGOING PHASE 1/2A TRIAL OF MP0533 IN AML AT ASH ANNUAL MEETING
07-12-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., DEC. 07, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS PRESENTS NEW DATA FOR DLL3 TARGETING RADIOTHERAPY MP0712 AT TRP SUMMIT EUROPE 2025, HIGHLIGHTING INITIAL HUMAN IMAGES AND MECHANISM OF ACTION
12-11-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., NOV. 12, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS PRESENTS ADDITIONAL PRECLINICAL PROOF-OF-CONCEPT DATA ON LOGIC-GATED CD3 SWITCH-DARPIN AT SITC 2025
03-11-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS REPORTS Q3 2025 FINANCIAL RESULTS AND CLINICAL PROGRESS, WITH DLL3-TARGETING RADIO-DARPIN MP0712 PHASE 1 LAUNCH EXPECTED IN 2025
30-10-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., OCT. 30, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PIPELINE PROGRESS FOR H1 2025
25-08-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., AUG. 25, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS AND ORANO MED PRESENT PRECLINICAL DATA ON MESOTHELIN-TARGETING RADIO-DARPIN CANDIDATE MP0726 AT SNMMI 2025
22-06-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS. AND PARIS, JUNE 22, 2025 (GLOBE NEWSWIRE) -- AD HOC...
Více zde
MOLECULAR PARTNERS ANNOUNCES PLANNED OPERATIONAL EFFICIENCIES AND EXTENSION OF CASH RUNWAY
10-06-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., JUNE 10, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS TO PRESENT AT UPCOMING INVESTOR CONFERENCES
19-05-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., MAY 19, 2025 (GLOBE NEWSWIRE) -- MOLECULAR PARTNER...
Více zde
MOLECULAR PARTNERS PRESENTS NEW PRECLINICAL DATA ON RADIO-DARPIN AND SWITCH-DARPIN PROGRAMS AT AACR 2025
25-04-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., APRIL 25, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCE...
Více zde
MOLECULAR PARTNERS ANNOUNCES ALL BOARD PROPOSALS APPROVED AT ANNUAL GENERAL MEETING
16-04-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., APRIL 16, 2025 (GLOBE NEWSWIRE) -- MOLECULAR PARTN...
Více zde
MOLECULAR PARTNERS TO HOLD THREE POSTER PRESENTATIONS AT AACR 2025
25-03-2025
UPDATE ON IND-ENABLING DATA FOR MP0712, A RADIO-DARPIN TARGETING DLL3 AND LABELED WITH 212 PB, CO-DE...
Více zde
MOLECULAR PARTNERS PUBLISHES INVITATION TO ANNUAL GENERAL MEETING 2025
25-03-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., MARCH 25, 2025 (GLOBE NEWSWIRE) -- MOLECULAR PARTN...
Více zde
MOLECULAR PARTNERS REPORTS HIGHLIGHTS FROM Q4 2024 AND KEY FINANCIALS FOR FULL YEAR 2024
06-03-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., MARCH 06, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCE...
Více zde
MOLECULAR PARTNERS ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR CONFERENCES AND 2024 FINANCIAL RESULTS CONFERENCE CALL
28-02-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., FEB. 28, 2025 (GLOBE NEWSWIRE) -- MOLECULAR PARTNE...
Více zde
MOLECULAR PARTNERS AND ORANO MED EXPAND PARTNERSHIP TO DEVELOP TARGETED ALPHA RADIO-THERAPIES FOR CANCER
12-01-2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., AND PARIS, JAN. 12, 2025 (GLOBE NEWSWIRE) -- AD HO...
Více zde
MOLECULAR PARTNERS TO PRESENT AT JP MORGAN HEALTHCARE CONFERENCE AND BAADER HELVEA SWISS EQUITIES CONFERENCE IN JANUARY
17-12-2024
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., DEC. 17, 2024 (GLOBE NEWSWIRE) -- MOLECULAR PARTNE...
Více zde
MOLECULAR PARTNERS PRESENTS CLINICAL DATA SUPPORTING ITS ONGOING MP0533 STUDY AND PRECLINICAL DATA ON NEXT-GEN CONDITIONING AGENT MP0621 AT ASH 2024
08-12-2024
MP0533 PHASE 1/2A DOSE ESCALATION STUDY CONTINUES WITH OVERALL ACCEPTABLE SAFETY PROFILE TO DATE AS ...
Více zde
MOLECULAR PARTNERS PRESENTS PRECLINICAL PROOF-OF-CONCEPT FOR CD3 SWITCH-DARPIN T CELL ENGAGER, CLINICAL BIOMARKER ANALYSES FOR MP0317 AT SITC 2024
07-11-2024
PRECLINICAL PROOF-OF-CONCEPT DATA SUPPORTS THE POTENTIAL OF CD3 SWITCH-DARPIN PLATFORM TO ACTIVATE A...
Více zde
MOLECULAR PARTNERS Q3 2024 INTERIM MANAGEMENT STATEMENT: MULTIPLE UPDATES ACROSS PORTFOLIO, RADIO-DARPIN CANDIDATE MP0712 PREPARING FOR CLINICAL ENTRY, MP0533 PHASE 1 ON-GOING
31-10-2024
RADIO-DARPIN THERAPY (RDT) CANDIDATE MP0712 SUPPORTED BY IN VIVO DATA PRESENTED AT THE EUROPEAN ASSO...
Více zde
MOLECULAR PARTNERS ANNOUNCES PRICING OF $20 MILLION UNDERWRITTEN OFFERING
25-10-2024
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., OCT. 25, 2024 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS AND ORANO MED STRENGTHEN AGREEMENT TO CO-DEVELOP 212PB-BASED RADIO-DARPIN THERAPEUTICS
22-10-2024
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., OCT. 22, 2024 (GLOBE NEWSWIRE) -- AD HOC ANNOUNC...
Více zde
MOLECULAR PARTNERS ANNOUNCES UPCOMING POSTER PRESENTATIONS AT THE 2024 SITC ANNUAL MEETING
04-10-2024
PRECLINICAL PROOF-OF-CONCEPT DATA SUPPORTS CD3 SWITCH-DARPIN PLATFORM FOR T CELL ENGAGERS WITH ENHAN...
Více zde
MOLECULAR PARTNERS ANNOUNCES UPCOMING TOP-RATED ORAL PRESENTATION ON MP0712, A ²¹²PB-LABELED RADIO-DARPIN THERAPEUTIC TARGETING DLL3 FOR SMALL CELL LUNG CANCER CO-DEVELOPED WITH ORANO MED, AT EANM 2024
27-09-2024
FIRST RDT CANDIDATE MP0712 SHOWS LOW KIDNEY ACCUMULATION AND HIGH TUMOR UPTAKE IN PRECLINICAL MODELS...
Více zde
MOLECULAR PARTNERS REPORTS H1 2024 CORPORATE HIGHLIGHTS AND FINANCIALS
26-08-2024
FIRST RADIO-DARPIN THERAPY (RDT) CANDIDATE MP0712 NOMINATED; SUPPORTING PRECLINICAL PACKAGE PRESENTE...
Více zde
MOLECULAR PARTNERS TO PRESENT AT THE TD COWEN RADIOPHARMACEUTICAL INNOVATION SUMMIT
17-06-2024
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., JUNE 17, 2024 (GLOBE NEWSWIRE) -- MOLECULAR PARTNE...
Více zde
MOLECULAR PARTNERS PRESENTS POSITIVE PRECLINICAL DATA FOR FIRST SWITCH-DARPIN CANDIDATE MP0621 AT EHA 2024
14-06-2024
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., JUNE 14, 2024 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
MOLECULAR PARTNERS AND ORANO MED SHARE POSITIVE PRECLINICAL DATA OF THEIR DLL3-TARGETING RADIO-DARPIN THERAPY (RDT) CANDIDATE MP0712 AT SNMMI 2024
11-06-2024
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS. AND PARIS, JUNE 11, 2024 (GLOBE NEWSWIRE) -- AD HOC...
Více zde
MOLECULAR PARTNERS PRESENTS POSITIVE DATA FROM COMPLETED PHASE 1 TRIAL OF MP0317 (FAP X CD40 DARPIN) MONOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS AT ASCO 2024
01-06-2024
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., JUNE 01, 2024 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEM...
Více zde
Dokumenty nejsou k dispozici
